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This study examined the inﬂuence of insulin resistance and inﬂammation on the association between body composition and
cognitive performance in older adults, aged 60–69 and aged 70 and older. Subjects included 1127 adults from NHANES 1999–
2002. Body composition was categorized based on measurements of muscle mass and waist circumference as sarcopenic nonobese,
nonsarcopenic obese, sarcopenic obese, and normal. Using OLS regression models, our ﬁndings suggest body composition is
not associated with cognitive functioning in adults ages 60–69; however, for adults aged 70 and over, sarcopenia and obesity,
either independently or concurrently, were associated with worsecognitive functioningrelativetonon-sarcopenicnon-obeseolder
adults. Furthermore, insulin resistance accounted for a signiﬁcant proportion of the relationship between cognitive performance
and obesity, with or without sarcopenia. Additionally, although high CRP was signiﬁcantly associated with poorer cognitive
functioning in adults ages 60–69, it did not inﬂuence the association between body composition and cognitive performance.
This study provides evidence that age-related physiological maladaptations, such as metabolic deregulation, which are associated
with abdominal fat, may simultaneously contribute to lower cognition and muscle mass, reﬂecting a degradation of multiple
physiological systems.
1.Introduction
Both obesity and frailty or underweight status have been
identiﬁed as important risk factors for poor cognitive
functioning among older adults. White matter lesions and
cerebral atrophy have been found to be more common in
adults with a high body mass index (BMI) [1, 2], and midlife
measures of central obesity have been found to predict poor
performance on tests measuring executive functioning and
visuomotorskills[3].Itisalsotruethatbeingunderweightor
frail may be linked to cognitive performance. Sturman et al.
found a curvilinear association between BMI and cognition
at baseline; however, after 6 years, subjects who were under-
weight experienced greater cognitive decline than normal
weight subjects, while obese subjects did not have signiﬁcant
declines in cognition [4]. Given that the impact of body
compositionisnotfullyunderstood,moreresearchisneeded
to further uncover the mechanisms driving the association.
Furthermore, little information currently exists regarding
the conﬂuence of body composition phenotypes and the
physiological mechanisms which directly or indirectly aﬀect
cognitive performance.
As individuals age, increases in fat mass are hypothesized
to stem from reductions in physical activity and retained
caloric intake levels in the presence of a declining basal
metabolic rate [5]. Concurrently, many individuals also ex-
perience signiﬁcant declines in muscle mass and strength
with aging, referred to as sarcopenia [6–8]. Age-related
changes in muscle mass and adiposity may stem from a
mutual pathophysiological mechanism. It has been proposed
that systemic inﬂammation and insulin resistance may play a
partintheconcurrenceofabdominalobesityandsarcopenia.
Proinﬂammatory cytokines are synthesized and secreted
by adipocytes [9] and may promote the breakdown of
skeletal muscle ﬁber diameter and protein content, as well
as disrupt muscle force production and fatigue resistance
[10]. Additionally, insulin resistance, which is often observed
in subjects with excess visceral adiposity, due to increases2 Current Gerontology and Geriatrics Research
in cytokine production [11], is believed to contribute to
metabolic deterioration of skeletal muscle, manifesting clin-
ically as sarcopenia [12].
Age-relatedalterationsininﬂammationandinsulinresis-
tance may also have implications for cognitive functioning
and may partially explain the associations between poor
cognitive performance and body composition. Systemic in-
ﬂammation has been identiﬁed as a potential risk factor for
cognitive impairment. In cross-sectional studies, increased
levels of CRP were associated with lower levels of executive
functioning and global cognition [13]. Furthermore, lon-
gitudinal studies have provided evidence that high levels
of CRP and IL-6 may accelerate the rate of cognitive im-
pairment for high functioning older adults [14]. Poor cog-
nitive functioning has also been associated with disruptions
in metabolic processing. The importance of the insulin-
signaling pathway has been identiﬁed as a factor facilitating
the maintenance of cognitive functioning ability. Further-
more, higher insulin resistance, as measured using the
homeostasis model of assessment (IRHOMA), has been found
to be associated with poorer cognitive eﬃciency and poorer
visual scanning with added cognitive ﬂexibility [15].
Insulin resistance, inﬂammation, cognitive functioning,
and body composition are strongly linked to aging and may
represent an age-related decline in multiple physiological
systems. Our study examines a nationally representative
sample of community-dwelling US citizens over the age of
60todeterminewhetherinsulinresistanceandinﬂammation
partiallyaccountfortheassociationsbetweencognitivefunc-
tioning and body composition. Because the variables being
examinedarecloselylinkedtoage[16,17],ouranalysisisrun
for two separate cohorts, in order to investigate whether
the inﬂuence is diﬀerent at various stages of old age. Fur-
thermore, to more precisely study the association between
cognitive performance and a diverse spectrum of body types
related to changes with age, we examine body composition
as a combination of abdominal adiposity and muscle mass
to facilitate our ability to examine an interaction between
obesity and frailty. Based on previous research, we hypoth-
esize that individuals who are sarcopenic obese will have
lowercognitiveabilitythannonsarcopenicnonobesesubjects
and that this association will be explained, in part, by high
levels of insulin resistance and CRP. Furthermore, because
cognitive functioning, body composition, and physiological
health deteriorate with age, we hypothesize that these asso-
ciations will be stronger among subjects aged 70 and over,
as compared to subjects aged 60–69.
2.MaterialsandMethods
2.1. Study Population. The study population was comprised
of males and females aged 60 and older from two subsamples
oftheUSNationalHealthandNutritionExaminationSurvey
(NHANES 1999–2002)—a nationally representative, cross-
sectional study conducted by the National Center for Health
Statistics (NCHS) [18]. Data were collected during at-home
interviews and at clinical and laboratory examinations, tak-
ing place at a Mobile Examination Center (MEC). Anthro-
pometric data measurements for body composition were
measured by dual X-ray adsorptiometry (DXA). Because of
the potential for nonresponse bias in the use of only cases
with information from the DXA scans, imputed data were
utilized in analysis as developed and recommended by
NHANES [18]. The NHANES ﬁles contain ﬁve sets of
imputed data for each eligible participant with missing DXA
data. While only one record was used in calculating sample
sizes, all ﬁve records were used in analyses to insure more
accurate variance estimates were obtained.
The total subsample size for eligible participants over age
60 from both NHANES 1999-2000 and 2001-2002 was 1630.
Due to missing data from the examination and laboratory
tests, those who were included in the study were 70% (N =
1127) of the original subsample, of whom 555 were aged 60–
69 and 572 were aged 70 and over. The subsample included
individuals who were tested for plasma glucose in a morning
laboratoryexamandwhohadfastedforeighttotwelvehours
before.Becauseindividualswithdiagnoseddiabeteswerenot
asked to fast, those individuals were excluded from the study.
Further details of recruitment, procedures, and study design
are available through the U.S. Department of Health and
Human Services [18].
2.2. Cognitive Functioning. Cognitive functioning was based
on the score for the Wechsler Adult Intelligence Scale, Third
Edition (WAIS-III) Digit Symbol-Coding module adminis-
tered during the household interview. Scores are based on
the number of correctly drawn symbols, out of 133, within
a 120-second period. Subjects who were unable to complete
the cognitive performance task without assistance were not
given scores and, therefore, not included in our analysis.
The scale is considered to be a more precise indicator of
diminished cognitive skills than the Minimental Status Exam
and has been administered in the Health ABC study from the
National Institute on Aging [18].
2.3. Body Composition. Body composition measurements
included waist circumference, weight, height, and skeletal
muscle mass (SMM). Body weight was measured using
standardizedproceduresandequipmentandwasrecordedto
the nearest 0.01kg by electronic scale. Waist circumference
was measured to the nearest 0.1cm starting on the right side
ofthebodyattheiliaccrest.Measurementsforregionalbone,
fat, and lean-tissue content were collected by whole body
DXA scans. We estimated SMM using measurements of
total lean muscle mass. Lean mass was estimated from DXA
measurements in kilograms. Subjects with an SMM less than
one standard deviation below the mean of a young refer-
ence group, which included males and females ages 20–39
fromNHANES1999–2003,wereclassiﬁedassarcopenic.The
cutoﬀs derived from the reference group were 48.37kg for
malesand34.57kgforfemales.Waistcircumferencewasused
to deﬁne obesity given that it is less likely to be confounded
with muscle mass than is body mass index (BMI). Further-
more, given that insulin resistance and inﬂammation are
more closely associated with abdominal adiposity in com-
parison with other types of fat, we chose to use waist
circumference given its ability to predict abdominal tissue
mass located in the midsection. Obesity was deﬁned as waistCurrent Gerontology and Geriatrics Research 3
circumference greater than 102cm for males and 88cm for
females [19]. Because our obesity and sarcopenia measures
m a yb ec o n f o u n d e db yh e i g h t ,w ei n c l u d e dam e a s u r eo f
standing height (in cm) as a control during analysis. Based
on these cutoﬀs, four categorical groups were created—
solelysarcopenic,solelyobese,sarcopenicobese,andnormal.
Finally, although there is no cutoﬀ for the lower end of
waist circumference, 95.5% of subjects who would have been
classiﬁedasunderweightusingBMI(<18.5)werecapturedin
the sarcopenic nonobese group while the remaining 5% were
in the reference group due to their healthy levels of muscle
mass.
2.4. Insulin Resistance and Inﬂammation. Insulin resistance
was determined through the use of the homeostasis model
assessment (IRHOMA)[ 20]. IRHOMA is relevant to epidemi-
ological studies and facilitates the estimation of insulin
resistance using plasma glucose and insulin. It has also been
shown to closely correlate with the insulin sensitivity index
[21]. IRHOMA was calculated as the product of fasting glucose
(mmol/L) and fasting insulin (μU/mL) divided by 22.5 [22].
CRP in a nonspeciﬁc indicator of general levels of systemic
inﬂammation.InNHANES1999–2002,high-sensitivityCRP
assays were performed on blood samples using a Behring
Nephelometer for quantitative CRP determination [18].
2.5. Potential Confounders. Age, sex, race/ethnicity, educa-
tion, low physical activity level, and history of cardiovascular
disease(CVD)werecollectedviaself-reportduringtheinter-
view. In analysis, these were used as control variables as they
have been found to relate to obesity, sarcopenia, and cogni-
tivedecline[23–29].IntheNHANESdata,agewasmeasured
as a continuous variable, in years, and top-coded at 85 in
order to guarantee anonymity among the oldest-old sample.
Because cognitive functioning, adiposity, muscle mass, sys-
temic inﬂammation, and insulin sensitivity are strongly
linked to aging, our analysis is performed separately for the
youngerpartofthesample,thoseaged60–69,andthoseaged
70 and over. In our analysis for the younger group, a con-
tinuous measure of age was used as a control; however, due
to top coding in NHANES, four age groups—70–74 years,
75–79 years, 80–84 years, and ages 85+ years—were used in
the70andovergroup.Fourcategoriesforrace/ethnicitywere
constructed using dummy variables to classify participants
as non-Hispanic whites, non-Hispanic blacks, Hispanic, or
other, with non-Hispanic whites used as a reference category.
Education was assessed as years of school completed. Low
physical activity level was assessed by asking subjects to rate
their average physical activity level each day. Those who re-
ported that they sit and do not walk around very much
were coded as 1, while all others were coded as 0. CVD was
coded as 1 in subjects reporting ever being diagnosed with
one of the following: coronary heart disease, congestive heart
failure,myocardialinfarction,orstroke;allotherswerecoded
as 0.
Two indicators for poor nutritional status and dietary
deﬁciencies, hyperhomocysteinemia and hypoalbuminemia,
were also used as controls. These indicators have been found
to vary by age and relate closely to both body composition
and cognitive performance. Homocysteine is an amino acid
that at elevated levels may signal nutritional deﬁciencies.
Total plasma homocysteine was measured using a ﬂuo-
rescence polarization immunoassay (FPIA) from Abbott
Diagnostics,“AbbottHomocysteine(HCY)assay.”Acutoﬀof
15μmol/L [30] was used to classify hyperhomocysteinemia.
Serum Albumin, a commonly utilized marker of nutritional
status [31], was measured using Boehringer Mannheim
Diagnostics. The Bromocresol purple binds selectively with
albumin, at the reaction pH [17]. Hypoalbuminemia was
deﬁned as serum albumin measures less than <3.8g/dL.
Although the typical cutoﬀ for hypoalbuminemia is reported
as3.5g/dL[32],ithasbeensuggestedthatamongoutpatients
this threshold may be too selective and could potentially
miss substantially at risk older adults [33] .T h u s ,am o r e
modest hypoalbuminemia level has been suggested for use
in population studies [34].
2.6. Statistical Analysis. SAS statistical software package ver-
sion 9.2 was used for all analyses. All analyses were run ac-
counting for the complex sampling procedures in NHANES
[20]. CRP and IRHOMA were log-transformed to give them a
more normal distribution and to better satisfy the assump-
tions of linear regression. Mean comparisons for cognitive
functioning, log-transformed IRHOMA, and log-transformed
CRP were examined by age category and body composition,
using a Bonferroni adjustment. A series of three ordinary
least squares regression models were run for each age group
todeterminewhetherinsulinresistanceand/orinﬂammation
impacted the association between body composition and
cognitive functioning. The ﬁrst model was used to determine
the association between body composition and cognitive
functioning, adjusting for demographic, health, and nutri-
tion variables, including age, race/ethnicity, sex, education,
height, history of CVD, physical activity, hypoalbuminemia,
and hyperhomocysteinemia. In models two and three, log-
transformed IRHOMA and log-transformed CRP were added
to the original model respectively.
3. Results
Demographic, physical, and examination characteristics of
the sample are listed by age group in Table 1. Approximately,
49.01% of subjects were 60–69 years of age with a median
age of 64, while 50.99% were 70 years of age and older
with a median age of 76. Participants were 53.63% and
60.23% female in the younger and older age groups,
respectively. Both groups were predominately non-Hispanic
white, 78.33% in the younger age group and 83.16% in the
older age group. The median education for both groups was
12years.Intheyoungergroup,23.51%hadlowdailyphysical
activity, 15.25% had CVD, 3.83 had hypoalbuminemia, and
4.71% had hyperhomocysteinemia. In the older age group,
thesepercentagesincreasedto30.76%withlowdailyphysical
activity, 24.70% with CVD, 5.11% with hypoalbuminemia,
and 11.20% with hyperhomocysteinemia.
Distributions of body composition, by age, are shown in
Figure 1. In the 60–69-year age group, 4.40% of the subjects
met criteria for sarcopenic obesity, 59.17% were solely4 Current Gerontology and Geriatrics Research
Table 1: Sample characteristics for subjects by age group.
Ages 60–69 Ages 70+
Age (years), median 64 76
Sex (female), (%) 53.63 60.23
Race/ethnicity, (%)
Non-Hispanic white 78.33 83.16
Non-Hispanic black 8.97 6.08
Hispanic 9.45 9.35
Other 3.24 1.41
Education (years), median 12.00 12.00
History of CVD 15.25 24.70
Low physical activity 23.51 30.76
Hypoalbuminemia 3.83 5.11
Hyperhomocysteinemia 4.71 11.20
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Figure 1: Distributions (%) of body composition by age.
obese, 12.63% were solely sarcopenic, and the remainder
(23.80%) were neither obese nor sarcopenic. In the 70 years
and over group, 7.04% of the subjects met criteria for
sarcopenic obesity, 48.12% were solely obese, 26.53% were
solely sarcopenic, and the remainder (18.30%) were neither
obese nor sarcopenic.
Means for cognitive functioning scores and medians for
IRHOMA and CRP are provided by body composition and age
inTable 2.Forbothagegroups,nonsarcopenicobesesubjects
had signiﬁcantly higher IRHOMA, followed by sarcopenic
obese subjects and, ﬁnally, sarcopenic nonobese subjects
and nonsarcopenic nonobese subjects, who had statistically
comparable levels of IRHOMA. In both age groups, cognitive
functioning scores and CRP diﬀered signiﬁcantly across all
fourbodycompositioncategories.Cognitivefunctioningwas
lowest among the sarcopenic obese group, followed by the
sarcopenic nonobese group, nonsarcopenic obese group, and
reference group. Sarcopenic obese subjects also had the
highest levels of CRP, followed by subjects in the nonsarco-
penic obese, sarcopenic nonobese, and the reference groups.
Table 3 examines the results from the three ordinary least
squares regression models for the 60–69 age group. None
of the unhealthy body composition groups were found to
be signiﬁcantly diﬀerent from the healthy reference group
in cognitive functioning score in any of the three models.
Insulin resistance was not signiﬁcantly related to cognitive
functioning in this age group. On the other hand, CRP was
found to be negatively associated with cognitive functioning.
In model 1, 47.2% of the variance in cognitive functioning
was explained by the variables in the equation. This is not
increased in either of the subsequent models.
Table 4 shows the results from the three ordinary least
squares regression models for the 70 and over age group.
In the ﬁrst model, all three sarcopenic and/or obese body
composition groups were associated with poorer cognitive
functioning. Relative to the healthy reference group, being
sarcopenic obese was associated with an estimated 7-point
decrease in cognitive functioning scores (β =− 7.08, P<
.0001), while being solely sarcopenic or solely obese was
associated with estimated decreases of approximately 4.2 and
1.5points,respectively(βsarcopenic nonobese =− 4.19,P<. 0001;
βnonsarcopenic obese =− 1.43, P<. 0001). In model 2, insulin
resistancewasfoundtohaveasigniﬁcantnegativeassociation
with cognitive functioning (β =− 3.02, P<. 0001).
The inclusion of log-transformed IRHOMA in the model
reduced the power of sarcopenic obesity to predict cognitive
functioning by over 20% (β =− 5.66, <.0001). Controlling
for insulin resistance also eliminated the association between
cognitive functioning and nonsarcopenic obesity (β =
−0.51, P = .489). In model 3, CRP was not found to be a
signiﬁcant predictor of cognitive functioning. Furthermore,
with the inclusion of CRP, the power of sarcopenic obesity,
sarcopenic nonobesity, or nonsarcopenic obesity to predict
cognitive functioning was not signiﬁcantly altered.
4. Discussion
Our ﬁndings suggest that body composition did not predict
cognitive functioning in adults ages 60–69; however, for
adults aged 70 and over, sarcopenia and obesity, either inde-
pendently or concurrently, are associated with lower cogni-
tive functioning when compared to nonsarcopenic nonobese
older adults. Furthermore, we found that insulin resistance
may account for a signiﬁcant proportion of the relationship
between cognitive performance and obesity, with or without
sarcopenia. These results are consistent with ﬁndings that
obesity, poor muscle quality, and insulin resistance [1–4, 15,
35] are associated with decreased cognitive functioning.
Age-related physiological maladaptations, such as met-
abolicderegulation,whichareassociatedwithabdominalfat,
may simultaneously contribute to lower cognition and mus-
cle mass, reﬂecting a degradation of multiple physiological
systems. Insulin resistance, which often occurs as a result
of the presence of excess visceral adiposity which increases
with age, has been shown to alter lipid metabolism, increase
systemic inﬂammation, disrupt endothelial functioning, and
impact prothrombotic status and atherosclerosis [36]. As
a result, many age-related diseases have been attributed to
the steady increase in insulin resistance over the lifespanCurrent Gerontology and Geriatrics Research 5
Table 2: Insulin resistance, CRP, and cognitive functioning comparisons by body composition and age group.
Measure Sarcopenic obese Nonsarcopenic obese Sarcopenic nonobese Reference group
Aged 60–69
IRHOMA, median 2.72 3.68 1.92 1.89
CRP (mg/L), median 6.40 3.40 1.90 1.40
Cognitive functioning, mean (SD) 49.59 (23.1) 53.61 (18.2) 50.37 (20.3) 54.80 (18.4)
Aged 70+
IRHOMA, median 2.86 3.19 1.89 1.70
CRP (mg/L), median 4.20 3.00 2.60 2.30
Cognitive functioning, mean (SD) 32.92 (15.8) 43.66 (17.7) 38.26 (15.2) 45.88 (15.4)
Table 3: Coeﬃcients predicting cognitive functioning for subjects aged 60–69.
Model 1 Model 2 Model 3
Sarcopenic obese −0.91 (1.30) −0.83 (1.30) −0.07 (1.31)
Solely sarcopenic 1.14 (0.93) 1.06 (0.93) 1.33 (0.93)
Solely obese 0.19 (0.62) 0.44 (0.68) 0.77 (0.64)
Black −15.71 (0.93)∗∗∗ −15.71 (0.93)∗∗∗ −15.52 (0.93)∗∗∗
Hispanic −12.03 (0.98)∗∗∗ −11.98 (0.98)∗∗∗ −12.19 (0.97)∗∗∗
Other −7.52 (1.47)∗∗∗ −7.39 (1.47)∗∗∗ −8.61 (1.49)∗∗∗
Age −1.08 (0.09)∗∗∗ −1.07 (0.09)∗∗∗ −1.06 (0.09)∗∗∗
Education 2.80 (0.09)∗∗∗ 2.80 (0.09)∗∗∗ 2.74 (0.10)∗∗∗
Female 9.25 (0.78)∗∗∗ 9.12 (0.79)∗∗∗ 9.48 (0.78)∗∗∗
Height 0.15 (0.04)∗∗∗ 0.15 (0.04)∗∗∗ 0.15 (0.04)∗∗
History of CVD −2.24 (0.72)∗∗ −2.21 (0.72)∗∗ −1.96 (0.72)∗∗
Low physical activity −3.12 (0.62)∗∗∗ −3.06 (0.62)∗∗∗ −3.11 (0.62)∗∗∗
Hypoalbuminemia −5.85 (1.29)∗∗∗ −5.58 (1.32)∗∗∗ −5.30 (1.29)∗∗∗
Hyperhomocysteinemia −4.98 (1.15)∗∗∗ −4.99 (1.15)∗∗∗ −4.97 (1.15)∗∗∗
IRHOMA −0.37 (0.39)
CRP −1.01 (0.24)∗∗∗
R squared .472 .472 0.475
∗P<. 05 ∗∗P<. 01 ∗∗∗P<. 001.
Table 4: Coeﬃcients predicting cognitive functioning for subjects aged 70+.
Model 1 Model 2 Model 3
Sarcopenic obese −7.08 (1.28)∗∗∗ −5.66 (1.28)∗∗∗ −7.19 (1.28)∗∗∗
Solely sarcopenic −4.19 (0.82)∗∗∗ −4.39 (0.82)∗∗∗ −4.20 (0.82)∗∗∗
Solely obese −1.43 (0.68)∗ 0.51 (0.73) −1.63 (0.69)∗
Black −14.33 (1.19)∗∗∗ −14.23 (1.18)∗∗∗ −14.40 (1.19)∗∗∗
Hispanic −9.19 (1.01)∗∗∗ −9.56 (1.01)∗∗∗ −9.33 (1.01)∗∗∗
Other −7.35 (2.03)∗∗∗ −7.40 (2.01)∗∗∗ −7.47 (2.03)∗∗∗
Age (75–79) −3.10 (0.59)∗∗∗ −2.91 (0.59)∗∗∗ −3.04 (0.59)∗∗∗
Age (80–84) −8.42 (0.68)∗∗∗ −8.07 (0.67)∗∗∗ −8.35 (0.68)∗∗∗
Age (85+) −12.02 (0.91)∗∗∗ −12.49 (0.91)∗∗∗ −12.03 (0.91)∗∗∗
Education 2.25 (0.08)∗∗∗ 2.21 (0.08)∗∗∗ 2.24 (0.08)∗∗∗
Female 3.68 (0.75)∗∗∗ 3.04 (0.75)∗∗∗ 3.80 (0.75)∗∗∗
Height −0.11 (0.04)∗∗ −0.13 (0.04)∗∗ −0.10 (0.04)∗
History of CVD −2.63 (0.61)∗∗∗ −2.42 (0.61)∗∗∗ −2.64 (0.61)∗∗∗
Low physical activity −3.11 (0.57)∗∗∗ −2.83 (0.56)∗∗∗ −3.14 (0.57)∗∗∗
Hypoalbuminemia −4.12 (1.44)∗∗ −4.35 (1.43)∗∗ −4.70 (1.45)∗∗
Hyperhomocysteinemia −0.11 (0.89) −0.27 (0.89) −0.26 (0.90)
IRHOMA −3.02 (0.45)∗∗∗
CRP 0.47 (0.24)
R squared .387 .397 0.388
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[36]. The association between insulin resistance and poor
cognitive functioning mayinvolve insulin-degrading enzyme
(IDE), which plays a role in both insulin and β-amyloid
metabolism. The accumulation of β-amyloid in the brain is
considered one of the earliest detectable signs in the progres-
sion of Alzheimer’s disease and is associated with cognitive
decline, neurodegeneration, and synaptic dysfunction [37].
Inthepresenceofinsulinresistance,excesscirculatinginsulin
maypromptanincreaseinβ-amyloidduetotheircompeting
demands for IDE [38].
Similarly, muscle weakness and deterioration, loss of
lower extremity mobility, and changes in body composition,
canalsobelinkedtoalterationsininsulinsensitivity[39,40].
Ithasbeensuggestedthatmuscle metabolism mayplay arole
inthedevelopmentofsarcopenia,giventhatimpairedinsulin
sensitivity has been shown to disrupt the anabolic eﬀects on
muscle proteins necessary for skeletal muscle conservation
[40, 41]. As a result obese individuals with high levels of
insulin resistance may be at increased risk of sarcopenia. On
the other hand, the conﬂuence of sarcopenia with obesity
m a yh a v ea ne v e ng r e a t e re ﬀect on insulin sensitivity, given
that reduced muscle mass decreases the availability of in-
sulin-responsive target tissue [42].
There are limitations in the present study which should
be noted. First, the use of cross-sectional data hindered our
ability to test for mediating factors or the temporality of our
associations. Without a longitudinal design, we are unable to
test whether insulin resistance precedes frailty and cognitive
declineorexaminewhethersubjectstransitionbetweenbody
composition categories as they age. Second, our cognitive
functioningvariablewasbasedonasinglemeasurewhichdid
not take into account multiple aspects of cognition. Third,
the use of imputed data on measures for muscle mass could
be considered a limitation even though this is the procedure
recommended by NCHS. Fourth, inﬂammation and insulin
resistance are measured at only one point in time and may
vary over time. Despite these limitations, the present study
is strengthened by the use of reliable techniques for mea-
suring body composition, the use of biomarkers to measure
insulin resistance and inﬂammation, inclusion of a large
representative random sample, and the use of appropriate
sample weights and procedures during analysis.
The current study provides preliminary evidence to
supportthehypothesisthatinsulinresistanceisanimportant
mediator to consider in the association between sarcopenia,
obesity, and cognitive functioning. With the doubling of
obesity prevalence over the last two to three decades, indus-
trialized countries are expected to experience a rise in the
incidence of sarcopenic obesity among the elderly. Fur-
thermore, given that both body composition and cognitive
functioning have important implications for quality of life,
healthcare costs, morbidity, and mortality, it is important to
identify the underlying biological mechanisms which may
predispose individuals to comorbidities, such as poor cog-
nitive functioning, adverse body composition, and insulin
resistance. In moving forward, the use of longitudinal data
and the development of appropriate and reliable deﬁnitions
for these conditions should facilitate our ability to under-
stand the pathophysiology of age-related comorbidities.
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